首页/数据集/Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor infiltrating CD8+ T cells

Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor infiltrating CD8+ T cells

ChEBI2014-12-18 更新2026-07-21 收录

免疫治疗机制

T细胞功能分析

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-58722 数据链接链接失效反馈

官方服务：

资源简介：

Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor infiltrating CD8+ T cells

应用场景：

创建时间：

2014-12-18

树突状细胞免疫调控

免疫治疗机制

To understand the mechanism of Pikfyve loss in dendritic cells, we cultured conventional dendritic cells isolated from the bone marrow of Pikfyvef/f (“WT”) and mice with ItgaxTg/0 Pikfyvef/f (“KO”) mi

NIAID Data Ecosystem70

Single cell RNA-seq data on human innate lymphoid cells.

先天淋巴样细胞功能

免疫治疗机制

Allergic rhinitis is a prevalent condition affecting up to 25% of the global population. Whilst common pharmacotherapies such as anti-histamines and corticosteroids can act as temporary symptom reliev

NIAID Data Ecosystem60

Figure S1 - Streptococcus pneumoniae Serotype 1 Capsular Polysaccharide Induces CD8+CD28? Regulatory T Lymphocytes by TCR Crosslinking

免疫调控机制

T细胞功能分析

Purity of CD8+CD28? and CD8+CD28? T cells. CD28? and CD28+ CD8+ cells for adoptive transfer studies were sorted by flow cytometry as described in the Materials and Methods section and evaluated for th

Figshare2015-12-02 更新30

Anti-PD-1 re-navigates concealed IL-15 to rejuvenate tumor-specific PD-1+CD8+T cells inside the tumor microenvironment

肿瘤免疫治疗

T细胞功能分析

The authors engineer an anti-PD-1-concealed sIL-15 fusion protein (αPD-1-IL-15-R), eliciting extraordinary antitumor immunity with negligible toxicity. αPD-1-IL-15-R largely expands tumor-specific CD8

NIAID Data Ecosystem70

Dose dependent nanoparticle albumin bound paclitaxel + pembrolizumab alters the immune micro environment in a esophageal homograft mouse model

免疫治疗机制

食管癌模型研究

Esophageal cancer has remained a therapeutic challenge despite the advancements in targeted therapy and immunotherapy. This study investigated the mechanism by which neoadjuvant pembrolizumab combined

Taylor & Francis Group2025-12-27 更新50

Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor infiltrating CD8+ T cells

资源简介：

相关数据集